⚠ Evidence note: Human outcome data on longevity interventions is limited; most claims rest on surrogate markers or animal models. Nothing here is medical advice.
Antifibrotic Lung Drugs
Current understanding
To be populated as evidence accumulates.
Evidence log
- 2026-06-27 — IL-11 neutralizing antibodies alleviate pulmonary fibrosis in aging mice by inhibiting TGF-β/NOX4/IL-11 signaling pathway.: cross-connection with il-11-neutralizing-antibodies: IL-11 blockade reverses the profibrotic phenotype of senescent lung fibroblasts in aged mice, positioning anti-IL-11 as a mechanistically distinct antifibrotic lead alongside existing lung antifibrotics. (novelty: 3)
- 2026-10-01 — Targeting senescence-associated fibrotic signatures identifies syringin as an effective modulator of the ATR/CHK1-p53 axis in idiopathic pulmonary fibrosis.: cross-connection with syringin: Preclinical bleomycin-IPF efficacy positions syringin alongside established antifibrotic lung drugs, but via a senescence-targeting mechanism rather than TGF-β or tyrosine-kinase blockade. (novelty: 3)
- 2026-09-11 — Lung Fibrosis Drug Lowers Biological Age Estimates: Lifespan Research Institute press coverage claims an unnamed lung-fibrosis drug lowered biological-age clock estimates; headline-only report with no primary data, drug identity, cohort size, or clock methodology disclosed. [expert-opinion] (novelty: 3)
Open questions
Related
Contributing findings
Lung Fibrosis Drug Lowers Biological Age Estimates
11-sep-2026
novelty 3
per-area 3
strengthens